Clinical value of PET/CT's SUV max at baseline, early follow-up, and end of treatment reevaluation as a prognostic factor in small cell lung cancer patients with extended disease.
Santiago Ponce Aix
No relevant relationships to disclose
Ray Manneh Kopp
No relevant relationships to disclose
Juan Manuel Sepulveda
No relevant relationships to disclose
Juan A. Núñez
No relevant relationships to disclose
Lara Iglesias
No relevant relationships to disclose
Tomas Pascual
No relevant relationships to disclose
Lucia Parrilla
No relevant relationships to disclose
Sebastian Ruiz Solis
No relevant relationships to disclose